Risk factors for 1-year mortality in patients with intermediate-stage hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization
Conclusion One-year mortality in patients with intermediate-stage HCC treated solely with TACE is not uncommon. High serum AFP level (> 400 ng/mL), CTP class B cirrhosis, and tumor size are independent risk factors for 1-year mortality in those patients.
Source: Advances in Digestive Medicine - Category: Gastroenterology Source Type: research
More News: Bilirubin | Cancer & Oncology | Carcinoma | Children | Cirrhosis | Gastroenterology | Hepatitis | Hepatitis B | Hepatitis C | Hepatocellular Carcinoma | Liver Cancer | Study | Women